Synaptic/Warner-Lambert in R&D deal
18 August 1997 00:00 [Source: ICB]
Synaptic Pharmaceutical Corp of New Jersey, US, and Warner-Lambert have signed a collaborative research and licensing deal covering identification and development of compounds that act on receptors for the neurotransmitter, galanin. Synaptic could receive up to $34m in milestone payments for the first two compounds identified. Possible indications include obesity, Alzheimer's, depression, pain and endocrine disorders.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Related Articles
- 05 Jun 07 23:00 CeNeRx announces agreement with PharmaNess Neuroscience to develop novel cannabinoid compounds
- 19 Mar 07 00:00 Memory Pharmaceuticals commences Phase IIa trial of MEM 3454 in Alzheimer's disease
- 23 Nov 05 00:00 Amarin announces significant neuroprotective effects of Miraxion.
- 14 Mar 05 00:01 Can the Slumping Pharmaceutical Industry Rebound?
- 17 Jan 05 00:01 Looking Beyond Big Pharma For Fine Chemicals Growth
- 17 Jan 05 00:01 Finding Opportunities in Early-Phase Development
- 06 Dec 04 15:51 Total recall
- 06 Dec 04 00:01 The Perils and Possibilities of the Pipeline
- 08 Nov 04 00:01 How Does Your Pipeline Grow?
- 04 Jul 04 23:01 Merck Adds to Its Growing Roster of Oncology Drugs
Latest News
- 09 Jan 09 13:13 Japan’s Kureha mulls moving forward Iwaki capacity expansions
- 09 Jan 09 12:17 Russia’s Gazprom pledges to restore gas supplies to Europe
- 09 Jan 09 12:00 NOON SNAPSHOT - Europe Markets Summary
- 09 Jan 09 11:51 Europe monthly acetone MMA net contract down €400/t
- 09 Jan 09 11:49 S&P revises Rompetrol outlook to negative
A time to look back and a time to look forward
Simon Robinson's Big Biofuels Blog